Cerebrospinal fluid cyclic guanosine 3′5′ monophosphate levels in Parkinson's disease

We measured CSF and plasma levels of cGMP in 22 patients with Parkinson's disease (PD) and in 28 age and sex-matched controls. PD patients had similar plasma cGMP levels than those of controls, although they showed a non-significant trend towards higher CSF cGMP levels ( P=0.07). PD patients tr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 1998-02, Vol.155 (1), p.92-94
Main Authors: Navarro, José Antonio, Jiménez-Jiménez, Félix Javier, Molina, José Antonio, Benito-León, Julián, Cisneros, Elena, Gasalla, Teresa, Ortı́-Pareja, Miguel, Tallón-Barranco, Antonio, de Bustos, Fernando, Arenas, Joaquı́n
Format: Article
Language:English
Subjects:
Cerebrospinal fluid
Cyclic GMP
Nitric oxide
Parkinson's disease
Plasma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We measured CSF and plasma levels of cGMP in 22 patients with Parkinson's disease (PD) and in 28 age and sex-matched controls. PD patients had similar plasma cGMP levels than those of controls, although they showed a non-significant trend towards higher CSF cGMP levels ( P=0.07). PD patients treated with levodopa showed significantly higher CSF cGMP levels than those not treated with this drug ( P
ISSN:0022-510X
1878-5883
DOI:10.1016/S0022-510X(97)00267-0